Gynofem Healthcare Unlisted Shares Price
vs. prev. close ₹60
52W High
₹60
52W Low
₹60
Market cap
₹595 Cr
IPO stage
No DRHP filed
CIN
U51909MP2016PTC040837
Price History
52W High
₹60
52W Low
₹60
About Gynofem Healthcare Unlisted Shares Price
Gynofem is a small, holding-company-backed pharma trading business still working through accumulated losses, with narrowing cash burn as the one clear positive trend - but a brand-intangible-heavy balance sheet and reliance on related-party funding mean this is a turnaround story to underwrite carefully, not a steady-state income play.
Short Version :
Gynofem Healthcare and Pharmaceuticals Limited is an Indore (Madhya Pradesh)-based pharmaceutical products trading company, selling exclusively in the domestic market. On a standalone basis (the company has no subsidiaries), FY26 revenue was Rs 5.02 crore, roughly flat against Rs 4.94 crore in FY25, while the company remained loss-making with a net loss of Rs 1.35 crore (narrower than FY25's Rs 2.09 crore loss). Book value stood at Rs 0.51 per share (Rs 0.64 FY25) on a face value of Rs 1, with EPS of Rs (0.14) (Rs (0.21) FY25) and ROE of negative 26.79% (negative 32.77% FY25). The balance sheet is dominated by a large Trademarks/Brands intangible asset (Rs 8.27 crore net, roughly 81% of total assets), and the company continues to depend on unsecured, related-party funding from its holding company to bridge recurring cash losses.
Why It Trades Where It Does :
Gynofem is a small, closely-held pharmaceutical trading entity, majority-owned (78.48%) by its holding company Gynofem Healthcare Private Limited, with the remaining promoter and public shareholding split among a handful of individuals and one institutional-style holder (Practibull Investment Services LLP, newly on the register in FY26 at 6.66%). The company has posted losses in both FY25 and FY26, though the loss narrowed by roughly 35% year-on-year and cash losses nearly halved (Rs 1.27 crore FY25 to Rs 0.62 crore FY26), which is the main improving signal in an otherwise weak financial profile. The balance sheet's dominant asset is an intangible Trademarks/Brands line that dwarfs the company's actual trading scale, and a meaningful share of its borrowings are unsecured loans from its own holding company rather than external lenders, both of which warrant close scrutiny ahead of any valuation.
Top Risk :
Accumulated losses have widened the negative reserves and surplus balance from Rs (3.53) crore to Rs (4.88) crore over FY25-FY26, eroding net worth from Rs 6.39 crore to Rs 5.04 crore even though paid-up share capital of Rs 9.92 crore has stayed unchanged.
The Trademarks/Brands intangible asset (Rs 8.27 crore net) constitutes about 81% of total assets, far larger than what this scale of pharmaceutical trading business would typically require; no impairment has been recognized, and realizability of this asset relative to the underlying cash-generating business is a material judgment call for investors.
A large share of borrowings (Rs 1.46 crore of Rs 1.94 crore long-term borrowings) are unsecured loans from the holding company, Gynofem Healthcare Private Limited, indicating the business is substantially sustained by related-party funding rather than independent operating cash flow or external credit.
Operating cash flow was negative in both years (Rs 0.48 crore outflow FY26, Rs 0.78 crore outflow FY25), funded by fresh borrowings (Rs 0.60 crore net financing inflow FY26) rather than operations.
Trade receivables aged 1-2 years grew sharply, from Rs 0.02 crore to Rs 0.25 crore year-on-year, suggesting some weakening in collection quality even as receivables overall grew.
The statutory auditor flagged that the company's accounting software did not maintain a complete audit-trail (edit-log) feature for all transactions during the year, a basic financial-reporting-infrastructure gap.
Top Opportunities :
The net loss narrowed by about 35% year-on-year and cash losses nearly halved, suggesting the business may be approaching an operational inflection point.
Revenue has been broadly stable across FY25-FY26 (Rs 4.94 crore to Rs 5.02 crore) despite the loss-making position, indicating the core trading operation itself is not shrinking.
The company carries no contingent liabilities, has no disputed statutory dues, has not defaulted on any borrowings, and the auditor found no indicators of fraud or going-concern uncertainty as at the report date.
A new institutional-style shareholder, Practibull Investment Services LLP, entered the register in FY26 with a 6.66% stake, a potential signal of external interest in the company.
Continued backing from the holding company, evidenced by recurring related-party loans, suggests promoter commitment to funding the business through its current loss-making phase.
Disclaimer :
Priveq.in is an informational platform for unlisted and pre-IPO shares, operated by Priveq Investech Private Limited (the named counterparty on transactions). Unlisted shares carry risks including illiquidity, valuation uncertainty, and limited regulatory disclosure. This page is informational only and does not constitute investment advice.
Company Details
Industry
Healthcare & Hospitals
Founded
2016
Headquarters
Indore, Madhya Pradesh, India
Min Lot Size
1
Total Shares
99213898
Regulatory Information
Corporate Identity Number (CIN)
U51909MP2016PTC040837
PAN Number
AAGCG4141F
ISIN
INE0NLL01017
Key Valuation Ratios
Valuation
Market Cap
₹595.28 Cr
P/E Ratio
—
Not meaningful — loss-making
P/S Ratio
118.65×
P/B Ratio
118.16×
EV / EBITDA
432.80×
Returns & Per Share
ROE
-26.79%
EPS
₹-0.14
Book Value / Share
₹0.51
Solvency
Debt / Equity
0.58×
Interest Coverage
-1.16×
Company Fundamentals
As of FY2026 Annual · updated 20 Oct 2026Gross Profit
₹3.98 Cr
EBITDA
₹1.38 Cr
Revenue Growth
1.49%
Profit Margin
-26.90%
Performance Trends
2 annual periods · derived from filed statements
Revenue
₹ Cr
Net Profit
₹ Cr · losses in red
Earnings Per Share
₹ per share
Return on Equity
ROE %
Return on Capital Employed
ROCE %
Debt-to-Equity
0.58×
EBITDA Margin
27.54%
Interest Coverage
-1.16×
Financial Statements
| Line item | FY2025 | FY2026 |
|---|---|---|
| Total Income | ||
| Revenue from operationsDisclosed | 4.94₹ Crore | 5.02₹ Crore |
| Other incomeDisclosed | 3₹ Thousand | 5₹ Thousand |
| Total IncomeDerived | 4.94₹ Crore | 5.02₹ Crore |
| Expenses | ||
| Cost of goods soldDisclosed | 1.49₹ Crore | 1.04₹ Crore |
| Purchases of stock-in-tradeDisclosed | 25.87₹ Lakh | 17.02₹ Lakh |
| Changes in inventoriesDisclosed | 2.64₹ Crore | 2.25₹ Crore |
| Employee benefits expenseDisclosed | 14.88₹ Lakh | 18.45₹ Lakh |
| Finance costsDisclosed | 52.24₹ Lakh | 53.58₹ Lakh |
| Depreciation and amortization expenseDisclosed | 1.68₹ Crore | 2₹ Crore |
| Manufacturing expensesDisclosed | 0₹ Crore | 0₹ Crore |
| Operating expensesDisclosed | 0₹ Crore | 0₹ Crore |
| Other expensesDisclosed | 0₹ Crore | 0₹ Crore |
| Total ExpensesDerived | 6.73₹ Crore | 6.17₹ Crore |
| Profit | ||
| Exceptional itemsDisclosed | 0₹ Crore | 0₹ Crore |
| Profit before taxDerived | -1.79₹ Crore | -1.16₹ Crore |
| Current tax expenseDisclosed | 30.34₹ Lakh | 19.43₹ Lakh |
| Deferred tax expenseDisclosed | 0₹ Crore | 0₹ Crore |
| Tax expenseDisclosed | 30.34₹ Lakh | 19.43₹ Lakh |
| Profit After TaxDerived | -2.09₹ Crore | -1.35₹ Crore |
| Other comprehensive incomeDisclosed | 0₹ Crore | 0₹ Crore |
| Total Comprehensive IncomeDerived | -2.09₹ Crore | -1.35₹ Crore |
Express buy interest
No commitment — the desk will reach out
Current Price
₹60Secure & Verified Transaction
Unlisted shares are illiquid and carry higher market risks. Please read the Risk Disclosure before investing.
Talk to a Specialist
Get expert guidance on this investment
About Gynofem Healthcare Unlisted Shares Price unlisted shares
Indicative · updated dailyGynofem Healthcare Unlisted Shares Price unlisted share price today
Gynofem Healthcare Unlisted Shares Price unlisted share price today is ₹60 as of 20 October 2026.
Gynofem Healthcare Unlisted Shares Price — frequently asked questions
- What is the grey market price for Gynofem Healthcare Unlisted Shares Price?
No IPO is currently announced for Gynofem Healthcare Unlisted Shares Price, so no grey market exists; the price above reflects Priveq's own desk valuation.
- Has Gynofem Healthcare Unlisted Shares Price filed for an IPO, and when might it list?
Gynofem Healthcare Unlisted Shares Price has not filed a draft red herring prospectus, so no IPO is currently announced and no listing date has been set.
- How does Gynofem Healthcare Unlisted Shares Price compare to its listed peers?
There is no closely comparable listed company for Gynofem Healthcare Unlisted Shares Price in India today.
- Is Gynofem Healthcare Unlisted Shares Price on the SME or Mainboard IPO track?
Gynofem Healthcare Unlisted Shares Price has not filed a draft red herring prospectus, so no IPO track is set yet.
- What is Gynofem Healthcare Unlisted Shares Price's CIN and registered office?
Gynofem Healthcare Unlisted Shares Price's Corporate Identity Number is U51909MP2016PTC040837, registered at Indore, Madhya Pradesh, India.
- What is Gynofem Healthcare Unlisted Shares Price's market capitalisation?
Gynofem Healthcare Unlisted Shares Price's market capitalisation is approximately ₹595 crore, based on its current unlisted share price.
More in Healthcare & Hospitals
All Healthcare & Hospitals →- S3V Vascular Technologies Limited₹540-0.9%
- DANTECH DIGITAL DENTAL SOLUTIONS PRIVATE LIMITED₹450
- Royalcare Super Speciality Hospitals₹155-3.1%
- Ekkaa Electronics (India) Ltd.₹500
- Cremica Food Industries Limited₹175
- Omega Seiki Limited₹2,750
- Airlife Gases Private Limited₹1,800
- Abans Investment Managers Limited₹2,500
Buying, selling and holding unlisted shares
Applies to every company on Priveq- How do I buy Gynofem Healthcare Unlisted Shares Price unlisted shares?
Priveq Investech Private Limited is the named counterparty on every transaction. To buy Gynofem Healthcare Unlisted Shares Price unlisted shares: complete KYC once (PAN, Aadhaar, bank details, and demat account information — SEBI-compliant, typically approved within 24 hours), then submit your order through your Priveq dashboard specifying quantity. Our team confirms price and payment details with you directly. Once payment is confirmed, Gynofem Healthcare Unlisted Shares Price shares are transferred off-market straight to your demat account, with no pooling and no middlemen.
- How do I sell Gynofem Healthcare Unlisted Shares Price unlisted shares?
Submit an Express Sell Interest for Gynofem Healthcare Unlisted Shares Price through your Priveq dashboard, specifying quantity, the same way a buy order is placed. Priveq quotes you a bid price, which may differ from the live Buy price shown to buyers, since unlisted-share pricing works on a bid-ask basis rather than a single quote. Once you accept, you'll need to provide your Client Master List (CML), a cancelled cheque or bank details, and PAN. If you hold shares with CDSL, transfer can also be completed digitally via CDSL Easiest. You transfer Gynofem Healthcare Unlisted Shares Price shares to Priveq first, and payment follows once the transfer is confirmed received, typically the same day, T+1, or occasionally T+2, communicated to you directly. For sizeable transactions worth crores of rupees, an escrow arrangement can be used instead, at the sole consent of both parties.
- What is the minimum investment for Gynofem Healthcare Unlisted Shares Price unlisted shares?
Minimum investment varies by company and is shown as the Min Investment figure on this page. Gynofem Healthcare Unlisted Shares Price's minimum is ₹60.
- Is there a maximum investment limit?
There's no fixed maximum investment limit for Gynofem Healthcare Unlisted Shares Price unlisted shares. For sizeable transactions worth crores of rupees, an escrow arrangement can be used at the sole consent of both parties, the same mechanism available on the sell side.
- Is buying Gynofem Healthcare Unlisted Shares Price unlisted shares legal in India?
Yes. Buying and selling unlisted shares in India is legal and is subject to relevant SEBI regulations, including the mandatory lock-in period after listing, stamp duty, and depository participant charges on each transaction. Priveq's own KYC process is built to be SEBI-compliant.
- What is the lock-in period for Gynofem Healthcare Unlisted Shares Price unlisted shares?
Gynofem Healthcare Unlisted Shares Price has not filed a DRHP yet, so no listing date or lock-in period applies at this stage. Once an IPO is filed, this answer updates to reflect the applicable SME or Mainboard lock-in.
- What happens if Gynofem Healthcare Unlisted Shares Price's IPO is delayed or withdrawn?
If an IPO is delayed, shares remain unlisted and continue to trade on the desk at Priveq's indicative price, with no lock-in in effect until an actual listing happens. If a company formally withdraws its DRHP, the same applies: shares stay unlisted, with no lock-in period until and unless a fresh IPO process begins.
- How are capital gains on Gynofem Healthcare Unlisted Shares Price unlisted shares taxed?
If you sell unlisted shares, including Gynofem Healthcare Unlisted Shares Price, within 24 months of purchase, the gain is taxed as short-term capital gain at your applicable income tax slab rate. Beyond 24 months, it is taxed as long-term capital gain at 12.5 percent, without indexation benefit, under the rules effective from 23 July 2024. If Gynofem Healthcare Unlisted Shares Price lists and you sell after listing, the applicable tax treatment shifts to listed-security rates, with the holding period still measured from your original unlisted purchase date. This is general information, not tax advice; investors should confirm their specific position with a tax advisor.
- Can NRIs invest in Gynofem Healthcare Unlisted Shares Price unlisted shares?
Yes, on a non-repatriable basis. NRIs can invest using funds from an NRO account; sale proceeds stay within India unless repatriated separately under RBI's own limits. Priveq does not currently support repatriable investment (NRE/FCNR-funded), which would require the investee company to file additional RBI paperwork as foreign direct investment.
- Does Priveq charge a platform fee on top of the share price?
No. The price quoted to you is all-in; there is no separate platform fee or brokerage added on top.
- How does Priveq determine the desk price for Gynofem Healthcare Unlisted Shares Price?
Priveq's desk price reflects several inputs together, not a single formula: the seller's ask price at the time, current demand and supply on the platform for Gynofem Healthcare Unlisted Shares Price specifically, broader sentiment in the unlisted and pre-IPO market, how Gynofem Healthcare Unlisted Shares Price's sector and listed peers are trading, the company's own recent financial performance and IPO-stage developments, and recent transaction history where deals have actually closed.
Because unlisted shares trade over the counter rather than on an exchange, this price is indicative, not a continuously live quoted market price, and the actual deal price is confirmed with you directly before a transaction closes.
- Is Priveq SEBI-registered? Does it give investment advice?
Priveq is not a SEBI-registered stock exchange and not a SEBI-registered investment adviser. Priveq Investech Private Limited operates Priveq.in as a research and information platform for unlisted and pre-IPO shares, and is the named counterparty on transactions executed through the platform. Nothing on this page is investment advice; it's information to help you evaluate a company and decide for yourself.
- Am I eligible to invest through Priveq if I'm not an HNI?
Yes. Priveq isn't a stock exchange with membership restrictions, and investing isn't limited to HNIs. Depending on the company, entry points can start as low as ₹20,000, though the minimum for any specific company is shown as the Min Investment figure on its page.
- What documents do I receive after buying unlisted shares?
You receive an email acknowledging and confirming your order, along with a deal note or invoice recording the transaction details.
- What happens to my shares or money if a deal falls through?
Because Priveq is the direct counterparty on every transaction rather than just connecting a buyer and seller, this risk sits with Priveq, not with you. If a deal falls through after you've committed funds or shares, they remain safe, and Priveq guarantees a refund.